skip to Main Content

Do you have asthma, nasal polyps, and Samter’s Triad or Aspirin-Exacerbated Respiratory Disease (AERD)? If you would like to undergo an aspirin desensitization to help treat your symptoms, you may be eligible for a research study at Brigham and Women’s Hospital testing a new medication for the treatment of AERD.
The study drug, called ifetroban, inhibits the thromboxane receptor, which we believe plays a role in AERD. This drug has not yet been approved by the Food and Drug Administration (FDA).
To qualify for the study, you have to be 18-65 years old, have symptoms consistent with Samter’s Triad/AERD, and have asthma. The study involves 3 visits over an 8-week period and involves an aspirin desensitization procedure, blood and nose fluid sampling, and urine tests. You will be seen by a medical doctor and will receive the study medication at no cost.
The purpose of this study is to find out if taking ifetroban will help treat the symptoms of AERD and prevent reactions to aspirin. Compensation is up to $225. For more information, please contact the Asthma Research Center at 1-888-99-ASTHMA (278462) or Dr. Tanya Laidlaw at tlaidlaw@partners.org

Back To Top